Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  138,594 results for ""Myelodysplastic Syndromes""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes.

  • Authors : Creignou M; Center for Hematology and Regenerative Medicine (HERM), Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.; Phase 1 Unit, Center for Clinical Cancer Studies, Karolinska University Hospital, Stockholm, Sweden.

Subjects: Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/therapy ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/diagnosis ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/mortality

  • Source: Journal of internal medicine [J Intern Med] 2024 Jul; Vol. 296 (1), pp. 53-67. Date of Electronic Publication: 2024 Apr 23.Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 8904841 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes.

  • Authors : Zhang F; RNA Institute, Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan, China.; Sun J

Subjects: Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/genetics ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/drug therapy ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/pathology

  • Source: British journal of cancer [Br J Cancer] 2024 Jul; Vol. 131 (2), pp. 231-242. Date of Electronic Publication: 2024 May 28.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

Screening of Myelodysplastic Syndromes Using Research Parameters of Complete Blood Count: Automated Detection of Dysplasia.

  • Authors : Urrechaga E; Hematology Laboratory, Hospital Universitario Galdakao -Usansolo, Galdakao, Vizcaya, Spain. Electronic address: .

Subjects: Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/diagnosis ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/blood; Humans

  • Source: Clinics in laboratory medicine [Clin Lab Med] 2024 Sep; Vol. 44 (3), pp. 387-396.Publisher: Elsevier Health Sciences Division Country of Publication: United States NLM ID: 8100174 Publication Model: Print Cited Medium: Internet

Record details

Read More Add to Saved list
×
Academic Journal

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.

Subjects: Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/therapy ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/genetics ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/diagnosis

  • Source: Leukemia & lymphoma [Leuk Lymphoma] 2024 Sep; Vol. 65 (9), pp. 1233-1244. Date of Electronic Publication: 2024 May 07.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

GSH exhaustion via inhibition of xCT-GSH-GPX4 pathway synergistically enhanced DSF/Cu-induced cuproptosis in myelodysplastic syndromes.

  • Authors : Li H; Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China.; Li Y

Subjects: Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/drug therapy ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/metabolism ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/pathology

  • Source: Free radical biology & medicine [Free Radic Biol Med] 2024 Sep; Vol. 222, pp. 130-148. Date of Electronic Publication: 2024 Jun 11.Publisher: Elsevier Science Country of Publication: United States NLM ID: 8709159 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

[Clinical Characteristics and Prognosis of Myelodysplastic Syndromes Patients with RUNX1 Gene Mutation].

  • Authors : Chen Y; Department of Hematology, The Second Affiliated Hospital (Tangdu Hospital) of Air Force Medical University, Xi'an 710038, Shaanxi Province, China.; Ji YR

Subjects: Core Binding Factor Alpha 2 Subunit*/Core Binding Factor Alpha 2 Subunit*/Core Binding Factor Alpha 2 Subunit*/genetics ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/genetics ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/diagnosis

  • Source: Zhongguo shi yan xue ye xue za zhi [Zhongguo Shi Yan Xue Ye Xue Za Zhi] 2024 Aug; Vol. 32 (4), pp. 1173-1180.Publisher: Zhongguo shi yan xue za zhi she Country of Publication: China NLM ID: 101084424 Publication Model: Print Cited Medium: Print ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Molecular prognostication for transplant decision making of patients with myelodysplastic syndromes: A retrospective single-center study.

  • Authors : Condorelli A; Department of Oncology and Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy; University of Milan-Bicocca, Monza, Italy.

Subjects: Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/therapy ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/genetics ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/mortality

  • Source: Leukemia research [Leuk Res] 2024 Jul; Vol. 142, pp. 107529. Date of Electronic Publication: 2024 May 26.Publisher: Pergamon Press Country of Publication: England NLM ID: 7706787 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.

  • Authors : Brar N; Department of Pathology, Stanford University School of Medicine, Stanford, CA, US.; Lawrence L

Subjects: Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/genetics ; Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/pathology ; Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/diagnosis

  • Source: American journal of clinical pathology [Am J Clin Pathol] 2024 Sep 03; Vol. 162 (3), pp. 269-281.Publisher: Oxford University Press Country of Publication: England NLM ID: 0370470 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.

  • Authors : Della Porta MG; Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy. Electronic address: .

Subjects: Epoetin Alfa*/Epoetin Alfa*/Epoetin Alfa*/therapeutic use ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/complications ; Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/Myelodysplastic Syndromes*/drug therapy

  • Source: The Lancet. Haematology [Lancet Haematol] 2024 Sep; Vol. 11 (9), pp. e646-e658. Date of Electronic Publication: 2024 Jul 19.Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial.

  • Authors : Díez-Campelo M; Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain; IBSAL, Instituto de investigación Biomédica de Salamanca, Salamanca, Spain. Electronic address: .

Subjects: Lenalidomide*/Lenalidomide*/Lenalidomide*/therapeutic use ; Lenalidomide*/Lenalidomide*/Lenalidomide*/adverse effects ; Lenalidomide*/Lenalidomide*/Lenalidomide*/administration & dosage

  • Source: The Lancet. Haematology [Lancet Haematol] 2024 Sep; Vol. 11 (9), pp. e659-e670. Date of Electronic Publication: 2024 Jul 18.Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  138,594 results for ""Myelodysplastic Syndromes""